Sleep News and Research

Latest Sleep News and Research

EMA accepts MAA filing of ViroPharma's Cinryze for HAE

ViroPharma Incorporated today announced that the European Medicines Agency (EMA) has accepted the filing of its Marketing Authorization Application for Cinryze for acute treatment and prophylaxis against hereditary angioedema, which was submitted through the centralized procedure in March 2010. ViroPharma is seeking European approval for both prevention and treatment of acute attacks of hereditary angioedema.

25 Mar 2010

American Association of Poison Control Centers: K2 herbal marijuana substitute spurred poison calls

K2, an herbal marijuana substitute also known as "spice," is a blend of herbs sprayed with a synthetic marijuana-like drug, and has spurred at least 112 calls to U.S. poison centers since 2009, including 59 calls since March 1, 2010.

25 Mar 2010

Study on zebrafish regenerate tissues links human heart implications

In a paper published in the March 25, 2010 issue of Nature, researchers working at the Salk Institute for Biological Studies and the Center of Regenerative Medicine in Barcelona (CMRB) identified a fish heart cell population that is the source of this astonishing healing feat, a finding that could provide insight into how mammalian hearts might be coaxed into repairing themselves after injury brought on by heart attack.

25 Mar 2010

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

25 Mar 2010

Bariatric surgery may delay onset of type 2 diabetes, says study

A team of researchers, led by a UC Davis veterinary endocrinologist, has shown for the first time that a surgical procedure in rats that is similar to bariatric surgery in humans can delay the onset of type 2 diabetes.

25 Mar 2010

FDA approves Custom Spine's anterior cervical interbody device

Custom Spine announced today that it has received FDA clearance to market PATHWAY ACIF, an anterior cervical interbody spacer. This cervical interbody device compliments the company's low-profile anterior cervical plate system, Regent ACP, which was released this past November.

25 Mar 2010

New ‘Revitalizing Q10 Eye Roller Gel’ for men

NIVEA For MEN formally announced the launch of the brand’s new Revitalizing Q10 Eye Roller Gel today, a men’s eye care product engineered to minimize the look of fine lines and reduce the appearance of dark circles and puffiness underneath the eyes.

24 Mar 2010

Transcept Pharmaceuticals receives second patent for Intermezzo formulation

Transcept Pharmaceuticals, Inc. today announced that the second patent covering the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office.

24 Mar 2010

Pfizer to supply pneumococcal conjugate vaccines for infants and children

Pfizer Inc. today announced it has signed a 10-year Provisional Supply Agreement to supply Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company’s 13-valent pneumococcal conjugate vaccine, for infants and young children in the world’s poorest countries under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease.

24 Mar 2010

Elderly patients with moderate sleep apnea live longer than their counterparts, says study

Findings from the Technion-Israel Institute of Technology could provide good news for elderly patients who suffer from sleep apnea. The research results from Prof. Peretz Lavie and Dr. Lena Lavie of the Faculty of Medicine show that elderly patients with moderate sleep apnea live longer than their counterparts in the general population.

24 Mar 2010

Johns Hopkins Hospital completes 100th kidney transplant

Surgeons at The Johns Hopkins Hospital have successfully completed their 100th kidney swap — a procedure popularized here to enlarge the pool of kidneys available for donation and provide organs to patients who might have died waiting for them.

24 Mar 2010

Researchers create audio CDs to encourage physical activity among school students

The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University $1.22 million to combat childhood obesity in the Bronx.

24 Mar 2010

Heavy drinkers more likely to have adverse health-related practices

Women and men who engage in frequent heavy drinking report significantly worse health-related practices, according to a Kaiser Permanente Center for Health Research study in the journal Addiction Research & Theory.

23 Mar 2010

Researchers devise simple water test to check for herbicide clomazone

University of California, Davis, scientists are helping rice farmers in Uruguay stop polluting their waterways -- including drinking-water sources and a globally valuable nature reserve.

23 Mar 2010

Adrenal fatigue: Vitamins, supplements may do more harm than good

Taking vitamins or supplements to treat “adrenal fatigue” may do more harm than good, says Todd Nippoldt, M.D., a Mayo Clinic expert in hormone disorders affecting the adrenal glands.

23 Mar 2010

Somaxon Pharmaceuticals to sell 4 million common stock shares

Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.

23 Mar 2010

Investigation on spread of illegal drug use in social networks

Recent studies have shown that behaviors such as happiness, obesity, smoking and altruism are "contagious" within adult social networks. In other words, your behavior not only influences your friends, but also their friends and so on.

20 Mar 2010

Mental activity during meditation is wakeful and relaxed, says study

Forget about crystals, candles, Eastern philosophy, and about sitting and breathing in awkward ways. Meditation research explores how the brain works when we refrain from concentration, rumination and intentional thinking.

20 Mar 2010

InvestorSoup.com announces investment report featuring Somaxon Pharmaceuticals

InvestorSoup.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

19 Mar 2010

Role of structured physical activity in preventing or delaying mobility disabilities in older adults

Wake Forest University Baptist Medical Center, together with Wake Forest University, will play a key role in a new study that seeks to determine whether a program of structured physical activity can prevent or delay major mobility disabilities in older adults.

19 Mar 2010